Who We Are
Object Pharma is an innovative fully integrated biopharma company dedicated to the development of new therapies for the treatment of mental illness. Our first indication is Major Depressive Disorder (MDD).
Object Pharma has a revenue generating division, called Metabiologics, that sells critical reagents to the botulinum neurotoxin community. These sales have allowed Object Pharma to self-fund the preclinical stage of our first product candidate, OP01.
health crisis in our lifetime.
treatments for mental health.
Our Team
Mike Jarpe, PhD
CEO/President
Rebecca Kerns, MBA
Chief Operating Officer
Dale Hollingshead, MBA
Chief Financial Officer
Aaron Chamberlian, PhD
Chief Science Officer
Eric Chojnicki, PhD
Vice President of Product Development
Dan Radecki, PhD
Vice President of Clinical Development
The Board of Directors
Kenton Abel, PhD
Executive Chairman
Mike Goodnough, PhD
Director
Aaron Chamberlian, PhD
Director
David Parker
Independent Director
Scientific Advisors
Michelle Magid, MD, MBA
President of Austin PsychCare, PA in Austin, Texas. Associate professor for the University of Texas Dell Medical School and for the Texas A&M Health Science Center
Michael E. Thase, MD
Professor, Psychiatry, Departments of Psychiatry, Perelman School of Medicine at the University of Pennsylvania
Steve Yoelin, MD
Leading practitioner, researcher, and trainer of neuromodulators, dermal fillers, and other medical aesthetic products in the United States with a successful private practice in Newport Beach, CA.